

Officers

Michael Stevens, MD
President

Madelaine Feldman, MD
Vice President

Gregory Schimizzi, MD
Treasurer

Gary Feldman, MD
Secretary

Directors

Jacob Aelion, MD
Director

Kostas Botsoglou
Director

Mark Box, MD
Director

Aaron Broadwell, MD
Director

Michael S. Brooks, MD, FACP, FACR
Director

Sarah Doaty, MD
Director

Michael Saitta, MD
Director

Michael Schweitz, MD
Director

Joshua Stolow, MD
Director

Headquarter Office

Julia Norwich
Associate Director

Kevin Daley
Government Relations

February 6, 2017

New Mexico House of Representatives
Representative Deborah A. Armstrong
Chair, House Health and Human Services Committee

Re: H.B. 260 – Relating to the regulation of biosimilar medications

Dear Honorable Chair Armstrong and Committee Members,

The Coalition of State Rheumatology Organizations (CSRO) is a national organization composed of approximately 35 state and regional professional rheumatology societies. CSRO formed by physicians to ensure excellence and access to the highest quality care for patients with rheumatologic, autoimmune, and musculoskeletal disease.

Rheumatologists are on the forefront of treatments for patients with autoimmune diseases. With the advent of biologic medications, we have been able to stop the progression of some of these diseases and avoid the development of life-long deformities. Biological products available for the treatment of rheumatoid arthritis and other autoimmune diseases have had a significant impact on improving our patients' quality of life, preventing deformities, disability and lowering mortality.

As you consider H.B. 260, CSRO wishes to convey its support for this important legislation, and thank Representative Armstrong for sponsoring its passage.

This bill provides important pathways for access to these unique medications. It also creates much needed patient safety rules including for dispensing pharmacists to communicate with physicians about biosimilar substitutions within 5 days. Requiring this communication as quickly as possible provides physicians an opportunity to counter and correctly report any adverse effects of medications.

With FDA approval of biosimilars, biological products continue to be of growing importance for rheumatology patients. CSRO supports the safe introduction of interchangeable biologic drugs into the practice of medicine in New Mexico and urges the passage of H.B. 260.

Respectfully,



Michael P. Stevens
President
Coalition of State Rheumatology Organizations